JP2009541236A5 - - Google Patents

Download PDF

Info

Publication number
JP2009541236A5
JP2009541236A5 JP2009515748A JP2009515748A JP2009541236A5 JP 2009541236 A5 JP2009541236 A5 JP 2009541236A5 JP 2009515748 A JP2009515748 A JP 2009515748A JP 2009515748 A JP2009515748 A JP 2009515748A JP 2009541236 A5 JP2009541236 A5 JP 2009541236A5
Authority
JP
Japan
Prior art keywords
branched
moiety
group
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009515748A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/005303 external-priority patent/WO2007147529A2/en
Publication of JP2009541236A publication Critical patent/JP2009541236A/ja
Publication of JP2009541236A5 publication Critical patent/JP2009541236A5/ja
Ceased legal-status Critical Current

Links

JP2009515748A 2006-06-20 2007-06-15 組換えウイルスワクチン Ceased JP2009541236A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06360028 2006-06-20
US85296406P 2006-10-20 2006-10-20
PCT/EP2007/005303 WO2007147529A2 (en) 2006-06-20 2007-06-15 Recombinant viral vaccine

Publications (2)

Publication Number Publication Date
JP2009541236A JP2009541236A (ja) 2009-11-26
JP2009541236A5 true JP2009541236A5 (https=) 2010-07-29

Family

ID=38657260

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515748A Ceased JP2009541236A (ja) 2006-06-20 2007-06-15 組換えウイルスワクチン

Country Status (15)

Country Link
US (1) US20100129403A1 (https=)
EP (1) EP2029169A2 (https=)
JP (1) JP2009541236A (https=)
KR (1) KR101141333B1 (https=)
CN (1) CN101472610A (https=)
AU (1) AU2007263281B2 (https=)
BR (1) BRPI0713711A2 (https=)
CA (1) CA2656266C (https=)
CR (1) CR10571A (https=)
IL (1) IL195683A0 (https=)
MA (1) MA30581B1 (https=)
MX (1) MX2008016036A (https=)
NO (1) NO20090194L (https=)
RU (1) RU2453335C2 (https=)
WO (1) WO2007147529A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI555531B (zh) 2009-08-07 2016-11-01 傳斯堅公司 用以治療b型肝炎病毒(hbv)感染之組成物
US9216213B2 (en) * 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Hbv聚合酶突變體
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
CN104640564B (zh) 2012-07-10 2020-08-04 特兰斯吉恩股份有限公司 分枝杆菌抗原疫苗
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
EP3092000A1 (en) 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
DK3169341T3 (da) 2014-07-16 2019-08-05 Transgene Sa Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
KR20190097240A (ko) 2016-12-28 2019-08-20 트랜스진 에스.에이. 종양용해성 바이러스 및 치료 분자
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
AU2020337690A1 (en) 2019-08-29 2022-04-07 Astellas Pharma Inc. Genetically engineered oncolytic vaccinia viruses and methods of uses thereof
TW202217002A (zh) 2020-07-13 2022-05-01 法商傳斯堅公司 免疫抑制之治療
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
KR20250034101A (ko) 2022-07-01 2025-03-10 트랜스진 계면활성제-단백질-d 및 tnfsf의 구성원을 포함하는 융합 단백질
CA3261778A1 (en) 2022-08-18 2024-02-22 Transgene CHIMERIC POXVIRUSES
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
EP0385630B1 (en) 1989-02-27 1996-11-27 Riker Laboratories, Inc. 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
SK287400B6 (sk) 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
GB0023008D0 (en) * 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
JP2005519990A (ja) 2001-10-12 2005-07-07 ユニバーシティ オブ アイオワ リサーチ ファウンデーション イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物
DK1487485T3 (da) * 2002-03-19 2011-03-14 Powderject Res Ltd Imidazoquinolinadjuvanser til DNA-vacciner
AU2004266162A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
EP1804583A4 (en) * 2004-10-08 2009-05-20 3M Innovative Properties Co ADJUVANT FOR DNA VACCINE

Similar Documents

Publication Publication Date Title
JP2009541236A5 (https=)
CA2656266A1 (en) Recombinant viral vaccine
RU2018116351A (ru) Пиримидиновое соединение
Patel et al. Novel drugs targeting Toll-like receptors for antiviral therapy
JP2007511546A5 (https=)
JP2011529918A5 (https=)
NL300899I2 (nl) Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit en Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie B01 eiwit
JP2014506907A5 (https=)
CA2400562A1 (en) Hybrid expression of neisserial proteins
JP2012528892A5 (https=)
JP2012092103A5 (https=)
JP2002541233A5 (https=)
JP2008501000A5 (https=)
JP2020500916A5 (https=)
JP2016503029A5 (https=)
JP2015512946A5 (https=)
JP2013507423A5 (https=)
JP2003501474A5 (https=)
JP2015533841A5 (https=)
JP2009523777A5 (https=)
JP2011246469A5 (https=)
JP2014518841A5 (https=)
JP2012532883A5 (https=)
JP2014028916A5 (https=)
AU2003246373A8 (en) Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions